Pyxis Oncology, Inc.

PYXS • Biotechnology

$1.87

▲ +0.03 (+1.62%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$119.28M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.35Liquidez saludable · 3.41Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 13 ago 2026, 12:50 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.87

Change1.62%

Shares Out63.99M

Market Cap$119.28M

Enterprise Value$104.12M

52W Range1.03 - 5.55

Beta1.32

P/E-1.34

P/S10.81

P/B10.43

P/FCF-1.76

EV/Sales9.43

Price$1.87

Change1.62%

Shares Out63.99M

Market Cap$119.28M

Enterprise Value$104.12M

52W Range1.03 - 5.55

Beta1.32

P/E-1.34

P/S10.81

P/B10.43

P/FCF-1.76

EV/Sales9.43

EV/EBITDA-1.21

EV/FCF-1.53

Earnings Yield-74.39%

FCF Yield-56.94%

Dividend Yield0.00%

Gross Margin82.77%

Oper. Margin-6.09%

Profit Margin-5.75%

Debt/Eq0.35

Current Ratio3.41

Quick Ratio3.41

Target$7.67

Target Upside310.20%

Target Median$8.00

Target Range7.00 - 8.00

Volume1.93M

Avg Volume833.72K

EPS Surprise-0.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

75/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

76/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.35Liquidez saludable · 3.41Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

PYXS

Analyst sentiment

Based on 12 analyst votes · 2026-10-20

92/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$6.00

Promedio

$6.50

Mediana

$6.50

Alto

$7.00

Resumen de la compañía

IPO: 10/8/2021

Industria: Biotechnology

P/B i: 10.43

Deuda / Patrimonio i: 0.35

Margen operativo: -609.18%

Margen neto: -574.55%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.35

Ratio corriente: 3.41

Ratio rápido: 3.41

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

GordonMD Global Investments LP

Transacción: 06/30/2026

OTRO

Cambio

+4,900,039

Precio

$3.29

Presentación

07/10/2026

Tipo

OTRO

GordonMD Global Investments LP

Transacción: 06/30/2026

OTRO

Cambio

Precio

Not reported

Presentación

07/10/2026

Tipo

OTRO

Dupont Jakob

Transacción: 06/30/2026

VENTA

Cambio

-35,000

Precio

$3.06

Presentación

07/02/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
GordonMD Global Investments LP	OTRO	+4,900,039	$3.29	06/30/2026	07/10/2026
GordonMD Global Investments LP	OTRO	0	Not reported	06/30/2026	07/10/2026
Dupont Jakob	VENTA	-35,000	$3.06	06/30/2026	07/02/2026
Dupont Jakob	VENTA	-35,000	$1.60	06/30/2026	07/02/2026
Palani Santhosh	COMPRA	+45,867	$1.36	03/24/2026	03/25/2026
HUMPHREY RACHEL	COMPRA	+45,867	$1.36	03/24/2026	03/25/2026
Cline Darren S	COMPRA	+45,867	$1.36	03/24/2026	03/25/2026
Lewis-Hall Freda C	COMPRA	+45,867	$1.36	03/24/2026	03/25/2026
Metzger Michael A	COMPRA	+45,867	$1.36	03/24/2026	03/25/2026
FLAVIN JOHN L	COMPRA	+45,867	$1.36	03/24/2026	03/25/2026
Wadhane Jitendra	COMPRA	+262,635	$1.36	03/24/2026	03/25/2026
Wadhane Jitendra	COMPRA	+109,461	Not reported	03/24/2026	03/25/2026
Dupont Jakob	COMPRA	+45,867	$1.36	03/24/2026	03/25/2026
HUMPHREY RACHEL	VENTA	-13,896	$1.03	04/21/2025	03/25/2026
HUMPHREY RACHEL	VENTA	-200	$0.97	04/17/2025	03/25/2026
HUMPHREY RACHEL	VENTA	-1,400	$0.97	04/14/2025	03/25/2026
Civik Thomas	COMPRA	+690,131	$1.49	02/03/2026	02/05/2026
FLAVIN JOHN L	COMPRA	+36,979	$0.98	03/31/2025	04/02/2025
Connealy Pamela Ann	COMPRA	+414,163	$0.98	03/31/2025	04/02/2025
Civik Thomas	COMPRA	+36,979	$0.98	03/31/2025	04/02/2025

Sobre la compañía

Pyxis Oncology, Inc.

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

Fuente - Link

Competidores

AVIR CRBU ENTA FHTX HUMA IMRX TNYA VYGR ZURA

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysis

Precigen (NASDAQ: PGEN - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk. Institutional and Insider Ownership 33.5% of Precigen shares are

Defense World

Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D

PYXS's main value driver is MICVO. This is an oncology drug candidate that could be useful for killing cancerous cells. MICVO's early data has been promising, but PYXS still has to find an adequate dose that's safe and effective. Fortunately, PYXS's recent raise helps their financing in the near term and should be enough for them to reach important clinical milestones with MICVO.

Seeking Alpha

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it closed its previously announced registered public offering (the "Offering") on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting discounts and commissions and other offering expenses. The Offering consisted of 36,047,919 shares of common stock at a public offering price of $2.90 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,883,121 shares of common stock at a public offering price of $2.899 per pre-funded warrant, in each case, accompanied by common warrants to purchase an aggregate of 49,310,352 shares of common stock.

GlobeNewsWire

Critical Survey: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)

Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Inovio Pharmaceuticals (NASDAQ: INO - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation. Earnings and Valuation This table compares Pyxis

Defense World

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previously announced registered public offering (the "Offering") of 36,047,919 shares of its common stock, or in lieu of common stock to certain investors, 1,883,121 pre-funded warrants to purchase shares of common stock, and accompanying common warrants to purchase 49,310,352 shares of common stock at an exercise price of $3.50. The combined public offering price for each share of common stock and accompanying common warrant is $2.90, and the combined public offering price for each pre-funded warrant and accompanying common warrant is $2.899 (equal to the combined public offering price per share of common stock and accompanying common warrant, minus $0.001), for expected gross proceeds to Pyxis Oncology of approximately $110 million, before deducting underwriting discounts, commissions and offering expenses. If all of the common warrants and pre-funded warrants are exercised in full, Pyxis Oncology would receive additional gross proceeds of approximately $172.6 million, before deducting applicable expenses.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-14	-0.35	-0.37	-0.02
2026-03-23	-0.35	-0.29	0.06
2025-11-03	-0.36	-0.35	0.01
2025-08-14	-0.36	-0.3	0.06
2025-05-15	-0.29	-0.35	-0.06
2025-03-18	-0.33	-0.32	0.01
2024-11-12	-0.32	-0.35	-0.03
2024-08-14	-0.33	-0.29	0.04
2024-05-14	-0.27	-0.06	0.21
2024-03-21	-0.49	-0.33	0.16
2023-11-07	-0.57	-0.56	0.01
2023-08-11	-0.66	-0.41	0.25